Immune reconstitution inflammatory syndrome associated with biologic therapy.
The use of biologics in the treatment of autoimmune disease, cancer, and other immune conditions has revolutionized medical care in these areas. However, there are drawbacks to the use of these medications including increased susceptibility to opportunistic infections. One unforeseen risk once opportunistic infection has occurred with biologic use is the onset of immune reconstitution inflammatory syndrome (IRIS) upon drug withdrawal. Although originally described in human immunodeficiency virus (HIV) patients receiving highly active antiretroviral therapy, it has become clear that IRIS may occur when recovery of immune function follows opportunistic infection in the setting of previous immune compromise/suppression. In this review, we draw attention to this potential pitfall on the use of biologic drugs.
Published In/Presented At
Gupta, M., Jafri, K., Sharim, R., Silverman, S., Sindher, S. B., Shahane, A., & Kwan, M. (2015). Immune reconstitution inflammatory syndrome associated with biologic therapy. Current allergy and asthma reports, 15(2), 499. https://doi.org/10.1007/s11882-014-0499-4
Medicine and Health Sciences
Department of Medicine